Login
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.

pacira.com

What Do They Do?

Sells non-opioid pain medicines and a handheld cold-treatment device for postsurgical and knee pain to healthcare providers.

How Do They Make Money?

Hospitals, surgery centers and provider offices order EXPAREL through wholesalers, while ZILRETTA goes mainly to specialty distributors and pharmacies; product sales are counted when transferred, and customers generally pay within zero to four months.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product sales
Sold outright

100%
FY2022: 100%
Royalty revenue
0.5%
FY2022: 0.4%

Who Are Their Customers?

Hospitals, surgery centers and provider offices order EXPAREL through wholesalers, which drop-ship to end users; ZILRETTA is sold mainly through specialty distributors and pharmacies to physicians, clinics and medical centers or hospitals. Pacira also contracts directly with healthcare providers and intermediaries such as group purchasing organizations.

Customers above 10% of revenue, FY2025
of revenue from three customers (31%, 26%, 22%)

Do Revenues Turn Into Profits?

Yes. It kept 1 cent of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.

Operating income, FY2025
3% of revenue
▲ Turned profitable vs FY2024 (−$73.4M, −10%)
Net income, FY2025
1% of revenue
▲ Turned profitable vs FY2024 (−$99.6M, −14%)
Free cash flow, FY2025
19% of revenue
▼ −24% vs FY2024 ($178.8M, 26%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −2%
vs $179.5M in Q3 FY2025
Net income
▲ +425%
vs $5.4M in Q3 FY2025
Net product sales share of revenue vs 99.2% in Q3 FY2025
  • Nov 5, 2026 Viatris launched a tender offer; Pacira withdrew its financial guidance The offer covers Pacira shares for $36.50 per share in cash; the merger would make Pacira a wholly owned Viatris subsidiary.
  • Oct 8, 2026 Pacira agreed to be acquired by Viatris Viatris would pay $36.50 per share in cash, with a tender offer followed by a merger subject to conditions.
  • Jun 28, 2026 Pacira agreed to sell its iovera business to Zimmer Biomet The agreement includes an upfront payment and potential additional payments tied to future sales; closing is subject to conditions.

Growing. Revenue grew 34% in 4 years, from $541.5M in FY2021 to $726.4M in FY2025, about 8% a year.

Gene therapy development The knee osteoarthritis gene therapy has moved from an early human study to a later stage of clinical testing.

Revenue over time
Net product sales Royalty revenue Collaborative licensing and milestone revenue
$1B$500M$0

Who Do They Compete With?

Competes with Avanos Medical

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support